0.28USD
12.16 MUSD
38.45 M
About AVROBIO, Inc.
Sector
Industry
CEO
Erik John Ostrowski
Website
Headquarters
Cambridge
Employees (FY)
13
Founded
2015
FIGI
BBG00DJ4T7D1
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of AVRO is 1.20 USD — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange AVROBIO, Inc. stocks are traded under the ticker AVRO.
AVROBIO, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
AVRO stock is 3.39% volatile and has beta coefficient of 1.27. Check out the list of the most volatile stocks — is AVROBIO, Inc. there?
One year price forecast for AVROBIO, Inc. has a max estimate of 2.00 USD and a min estimate of 2.00 USD.
AVRO earnings for the last quarter are −0.48 USD per share, whereas the estimation was −0.35 USD resulting in a −36.37% surprise. The estimated earnings for the next quarter are −0.35 USD per share. See more details about AVROBIO, Inc. earnings.
Yes, you can track AVROBIO, Inc. financials in yearly and quarterly reports right on TradingView.
AVRO stock has fallen by 6.25% compared to the previous week, the month change is a 4.00% fall, over the last year AVROBIO, Inc. has showed a 34.83% increase.
AVRO net income for the last quarter is −8.79 M USD, while the quarter before that showed −21.58 M USD of net income which accounts for 59.29% change. Track more AVROBIO, Inc. financial stats to get the full picture.
Today AVROBIO, Inc. has the market capitalization of 53.83 M, it has decreased by 4.58% over the last week.
No, AVRO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, AVRO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AVROBIO, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 13.00 employees. See our rating of the largest employees — is AVROBIO, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AVROBIO, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AVROBIO, Inc. stock shows the sell signal. See more of AVROBIO, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on AVROBIO, Inc. future price: according to them, AVRO price has a max estimate of 2.00 USD and a min estimate of 2.00 USD. Read a more detailed AVROBIO, Inc. forecast: see what analysts think of AVROBIO, Inc. and suggest that you do with its stocks.